Remove 2027 Remove Communication Remove Vaccines
article thumbnail

FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency

Pharmacy Times

Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.

FDA 97
article thumbnail

Piramal Pharma announces $90m investment to expand US sites

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches. A ground-breaking ceremony was held on 25 June 2025 to mark the commencement of work on Lexington’s site expansion.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Merck concludes SpringWorks acquisition for $3.4bn

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. Give your business an edge with our leading industry insights.

article thumbnail

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

FDA 52
article thumbnail

WHO endorses Gilead’s Yeztugo for HIV prevention

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? The WHO says that the vaccine offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options. The approval of Yeztugo was hailed as a historical breakthrough by HIV experts and charities. Sign up for our daily news round-up!

article thumbnail

Sanofi agrees to invest $25m in Adagene

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. As of December 2024, the company reported cash reserves of $85.2m.

article thumbnail

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Pharmaceutical Technology

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.